Replimune, Inc.
Clinical trials sponsored by Replimune, Inc., explained in plain language.
-
Cancer-fighting virus shows promise in liver cancer trial
Disease control Recruiting nowThis study tests a new treatment called RP2, a virus that attacks cancer cells, combined with other drugs for people with advanced liver or bile duct cancer that has not responded to first treatment. About 60 adults will take part. The goal is to see if the combination shrinks tu…
Phase: PHASE2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated May 26, 2026 06:17 UTC
-
New hope for advanced melanoma patients: experimental virus therapy combined with immunotherapy enters phase 3 trial
Disease control Recruiting nowThis Phase 3 study tests whether an experimental cancer-killing virus (vusolimogene oderparepvec) combined with the immunotherapy nivolumab works better than standard treatments for people with advanced melanoma that has worsened after prior immunotherapy. About 400 participants …
Phase: PHASE3 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for rare eye cancer: experimental combo takes on standard treatment
Disease control Recruiting nowThis study tests whether a new drug called RP2, given with nivolumab, works better than the standard combination of ipilimumab and nivolumab for people with metastatic uveal melanoma (a rare eye cancer that has spread). About 280 adults who have not had prior immunotherapy will r…
Phase: PHASE2, PHASE3 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
Researchers track 50 patients for 5 years after immunotherapy
Knowledge-focused Recruiting nowThis study watches 50 people who already received replimune immunotherapy for cancers like melanoma or liver cancer. The goal is to see if any side effects show up years later. No new treatment is given—just regular checkups for 5 years.
Sponsor: Replimune, Inc. • Aim: Knowledge-focused
Last updated May 20, 2026 11:53 UTC